The publication of positive Phase 1 data for NKTR-255 in combination with CAR-T therapy indicates a significant advancement in treatment efficacy for B-cell acute lymphoblastic leukemia. The doubling of survival rates compared to historical controls is likely to boost investor confidence and positively impact Nektar's stock price in the short term.